Evidence from prior research had shown that anti-EGFR antibody nimotuzumab could increase HLA class I expression in tumor cell lines (24), and another study found similar results showing that nimotuzumab can enhance NK cell activation and DC maturation and increase EGFR-specific T cell (25). The gene discussed is EGFR; the disease is neoplasm.